JPWO2019131964A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019131964A5 JPWO2019131964A5 JP2019562482A JP2019562482A JPWO2019131964A5 JP WO2019131964 A5 JPWO2019131964 A5 JP WO2019131964A5 JP 2019562482 A JP2019562482 A JP 2019562482A JP 2019562482 A JP2019562482 A JP 2019562482A JP WO2019131964 A5 JPWO2019131964 A5 JP WO2019131964A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- peg
- formula
- residue
- acid residue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000539 amino acid group Chemical group 0.000 claims 48
- 102000000588 Interleukin-2 Human genes 0.000 claims 43
- 108010002350 Interleukin-2 Proteins 0.000 claims 43
- 125000003275 alpha amino acid group Chemical group 0.000 claims 28
- 238000000034 method Methods 0.000 claims 23
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 10
- 239000004472 Lysine Substances 0.000 claims 8
- -1 o-azidobenzyl Chemical group 0.000 claims 8
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims 8
- 235000004279 alanine Nutrition 0.000 claims 2
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims 2
- IVRMZWNICZWHMI-UHFFFAOYSA-N azide group Chemical group [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 claims 2
- 108040006849 interleukin-2 receptor activity proteins Proteins 0.000 claims 2
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 claims 2
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 2
- 102000010789 Interleukin-2 Receptors Human genes 0.000 claims 1
- 108010038453 Interleukin-2 Receptors Proteins 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 235000001014 amino acid Nutrition 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 210000003289 regulatory T cell Anatomy 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2017252224 | 2017-12-27 | ||
| JP2017252224 | 2017-12-27 | ||
| PCT/JP2018/048361 WO2019131964A1 (ja) | 2017-12-27 | 2018-12-27 | Il-2改変体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JPWO2019131964A1 JPWO2019131964A1 (ja) | 2020-12-10 |
| JPWO2019131964A5 true JPWO2019131964A5 (cg-RX-API-DMAC7.html) | 2022-10-31 |
| JP7275049B2 JP7275049B2 (ja) | 2023-05-17 |
Family
ID=67067530
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019562482A Active JP7275049B2 (ja) | 2017-12-27 | 2018-12-27 | Il-2改変体 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US12280118B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3733693A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7275049B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102740971B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN111868079B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2018394189B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3086842A1 (cg-RX-API-DMAC7.html) |
| TW (1) | TW201930345A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019131964A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112019018915A2 (pt) | 2017-03-15 | 2020-04-14 | Pandion Therapeutics Inc | imunotolerância direcionada |
| AU2018273914A1 (en) | 2017-05-24 | 2019-11-14 | Pandion Operations, Inc. | Targeted immunotolerance |
| IL321812A (en) | 2017-08-03 | 2025-08-01 | Synthorx Inc | Cytokine complexes for the treatment of autoimmune diseases |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| USRE50550E1 (en) | 2017-12-06 | 2025-08-26 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| US12565525B2 (en) | 2018-03-28 | 2026-03-03 | Ascendis Pharma Oncology Division A/S | IL-2 conjugates |
| AU2019301697A1 (en) * | 2018-07-13 | 2021-01-07 | Il-2Rx, Inc. | Compounds, compositions, methods, and uses for treating cancer and immunological disorders |
| CA3098930A1 (en) | 2018-09-21 | 2020-03-26 | Innovent Biologics (Suzhou) Co., Ltd. | Novel interleukin-2 and use thereof |
| TW202031284A (zh) | 2018-11-08 | 2020-09-01 | 美商新索思股份有限公司 | 介白素10結合物及其用途 |
| MA54952A (fr) | 2019-02-06 | 2022-05-11 | Synthorx Inc | Conjugués d'il-2 et méthodes d'utilisation de ceux-ci |
| AU2020279240A1 (en) | 2019-05-20 | 2021-12-23 | Pandion Operations, Inc. | MAdCAM targeted immunotolerance |
| AU2020329933A1 (en) * | 2019-08-15 | 2022-03-24 | Cytimm Therapeutics, Inc. | Modified interleukin 2 (IL-2) polypeptides, conjugates and uses thereof |
| CA3148135A1 (en) | 2019-08-23 | 2021-03-04 | Carolina E. CAFFARO | Il-15 conjugates and uses thereof |
| WO2021050554A1 (en) | 2019-09-10 | 2021-03-18 | Synthorx, Inc. | Il-2 conjugates and methods of use to treat autoimmune diseases |
| CN114437198A (zh) * | 2019-12-17 | 2022-05-06 | 北京志道生物科技有限公司 | 白介素-2衍生物 |
| WO2021143572A1 (zh) * | 2020-01-15 | 2021-07-22 | 天津键凯科技有限公司 | 一种制备结合位点可控的peg化生物分子的方法 |
| US11981715B2 (en) | 2020-02-21 | 2024-05-14 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a CD39 effector |
| KR102986821B1 (ko) * | 2020-04-22 | 2026-07-06 | 머크 샤프 앤드 돔 엘엘씨 | 인터류킨-2 수용체 베타 감마c 이량체에 대해 편향되고 비펩티드성 수용성 중합체에 접합된 인간 인터류킨-2 접합체 |
| CA3178074A1 (en) | 2020-06-03 | 2021-12-09 | Nina Gunnarsson | Il-2 sequences and uses thereof |
| WO2022081728A2 (en) * | 2020-10-14 | 2022-04-21 | Cytimm Therapeutics, Inc. | Modified interleukin 2 (il-2) polypeptides, and methods of making and using the same |
| CN113698468B (zh) * | 2021-09-01 | 2022-10-11 | 浙江新码生物医药有限公司 | 人白细胞介素2-聚乙二醇偶联物及其应用 |
| JP7864826B2 (ja) * | 2021-09-22 | 2026-05-25 | フォートビタ バイオロジクス(シンガポール)プライベート リミティド | インターロイキン2変異体およびその融合タンパク質 |
| CN116769013A (zh) * | 2022-03-10 | 2023-09-19 | 广东菲鹏制药股份有限公司 | 白细胞介素2突变体以及含有其的复合物 |
| CN115850436B (zh) * | 2022-10-14 | 2026-02-03 | 海徕科(北京)生物技术有限公司 | 白介素2突变体及其应用 |
| WO2024118780A2 (en) * | 2022-11-30 | 2024-06-06 | Binacea Pharma, Inc. | Il-2 mutants and uses thereof |
| EP4741410A1 (en) * | 2023-07-06 | 2026-05-13 | Glytech, Inc. | Solubilization group for poorly water-soluble proteins |
| IL330442A (en) * | 2024-01-08 | 2026-08-01 | Fbd Biologics Ltd | Engineered variants of IL-2 and methods for using them |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1388836A (en) | 1971-06-01 | 1975-03-26 | Medisan Ab | Cosmetic compositions |
| US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
| US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| EP0229108B1 (en) * | 1985-06-26 | 1990-12-27 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| US5417970A (en) | 1988-10-21 | 1995-05-23 | Sanofi | Drugs containing a glycosylated interleukin-2 |
| US4902502A (en) * | 1989-01-23 | 1990-02-20 | Cetus Corporation | Preparation of a polymer/interleukin-2 conjugate |
| US5153310A (en) * | 1989-02-28 | 1992-10-06 | Du Pont Merck Pharmaceutical Company | Il-2 analogs containing n-linked glycosylation sites |
| US5312903A (en) | 1990-06-01 | 1994-05-17 | E. I. Du Pont De Nemours And Company | Lysine-glycosylated recombinant interleukin-2 |
| ATE375363T1 (de) * | 1997-07-14 | 2007-10-15 | Bolder Biotechnology Inc | Derivate des wachstumshormons und verwandte proteine |
| US6955807B1 (en) | 1998-05-15 | 2005-10-18 | Bayer Pharmaceuticals Corporation | IL-2 selective agonists and antagonists |
| US7070959B1 (en) * | 1999-06-08 | 2006-07-04 | Regeneron Pharmaceuticals, Inc. | Modified chimeric polypeptides with improved pharmacokinetic properties |
| KR100775805B1 (ko) | 2001-06-19 | 2007-11-12 | 오츠카 가가쿠 가부시키가이샤 | 당쇄 아스파라긴 유도체의 제조 방법 |
| EP1421187B1 (en) | 2001-07-27 | 2007-10-10 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Systems for in vivo site-directed mutagenesis using oligonucleotides |
| EP1454138B1 (en) | 2001-12-04 | 2012-01-18 | Merck Patent GmbH | Immunocytokines with modulated selectivity |
| US7943763B2 (en) | 2002-07-05 | 2011-05-17 | Otsuka Chemical Holdings Co., Ltd. | Process for preparing glycopeptides having asparagine-linked oligosaccharides, and the glycopeptides |
| JP5087274B2 (ja) * | 2003-06-30 | 2012-12-05 | ドマンティス リミテッド | ポリペプチド |
| WO2005007121A2 (en) * | 2003-07-18 | 2005-01-27 | Massachusetts Institute Of Technology | Mutant interleukin-2(il-2) polypeptides |
| KR100731875B1 (ko) | 2003-07-28 | 2007-06-25 | 오츠카 가가쿠 가부시키가이샤 | 아미노화 복합형 당사슬 유도체 및 그의 제조방법 |
| CN1930300A (zh) * | 2004-03-05 | 2007-03-14 | 希龙公司 | 预测患者治疗药物耐受性的体外试验系统 |
| DE102008023820A1 (de) | 2008-05-08 | 2009-11-12 | Aicuris Gmbh & Co. Kg | Mittel zur Behandlung und/oder Prophylaxe einer Autoimmunerkrankung und zur Bildung von Regulatorischen T-Zellen |
| WO2010085495A1 (en) | 2009-01-21 | 2010-07-29 | Amgen Inc. | Compositions and methods of treating inflammatory and autoimmune diseases |
| ES2866674T3 (es) | 2010-11-12 | 2021-10-19 | Nektar Therapeutics | Conjugados de una fracción de IL-2 y un polímero |
| WO2013068874A1 (en) | 2011-11-11 | 2013-05-16 | Pfizer Inc. | Antibody-drug conjugates |
| US9738724B2 (en) | 2012-06-08 | 2017-08-22 | Sutro Biopharma, Inc. | Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use |
| WO2014028748A1 (en) | 2012-08-15 | 2014-02-20 | Irm Llc | Interleukin 2 antibodies and antibody complexes |
| US9670521B2 (en) | 2012-09-24 | 2017-06-06 | Medimmune Limited | Amino acid derivatives |
| WO2014124258A2 (en) | 2013-02-08 | 2014-08-14 | Irm Llc | Specific sites for modifying antibodies to make immunoconjugates |
| US9580486B2 (en) | 2013-03-14 | 2017-02-28 | Amgen Inc. | Interleukin-2 muteins for the expansion of T-regulatory cells |
| WO2015109212A1 (en) | 2014-01-17 | 2015-07-23 | Pfizer Inc. | Anti-il-2 antibodies and compositions and uses thereof |
| KR102493543B1 (ko) | 2014-07-21 | 2023-01-30 | 데리니아, 인크. | 자가면역 질환의 치료를 위한 조절 t 세포를 선택적으로 활성화시키는 분자 |
| JP6640834B2 (ja) | 2014-08-11 | 2020-02-05 | デリニア, インコーポレイテッド | 自己免疫疾患の処置のために調節性t細胞を選択的に活性化させる改変il−2変異体 |
| IL304950A (en) * | 2015-04-10 | 2023-10-01 | Amgen Inc | Interleukin for the expansion of myotonic control T-2 cells |
| JP6967221B2 (ja) | 2015-08-19 | 2021-11-17 | 国立研究開発法人理化学研究所 | 非天然アミノ酸導入抗体 |
-
2018
- 2018-12-27 CN CN201880083560.4A patent/CN111868079B/zh active Active
- 2018-12-27 CA CA3086842A patent/CA3086842A1/en active Pending
- 2018-12-27 KR KR1020207018206A patent/KR102740971B1/ko active Active
- 2018-12-27 US US16/958,045 patent/US12280118B2/en active Active
- 2018-12-27 EP EP18897857.1A patent/EP3733693A4/en not_active Withdrawn
- 2018-12-27 JP JP2019562482A patent/JP7275049B2/ja active Active
- 2018-12-27 TW TW107147546A patent/TW201930345A/zh unknown
- 2018-12-27 WO PCT/JP2018/048361 patent/WO2019131964A1/ja not_active Ceased
- 2018-12-27 AU AU2018394189A patent/AU2018394189B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7275049B2 (ja) | Il-2改変体 | |
| ES2374166T3 (es) | Dominios sushi de il-15ralfa como potenciadores selectivos y eficaces de la acción de il-15 a través de il-15rbeta/gamma, en las prote�?nas de fusión hiperagonistas il15ralfa sushi-il 15. | |
| JP2017523789A5 (cg-RX-API-DMAC7.html) | ||
| CN105324397B (zh) | 胰岛素-肠促胰岛素缀合物 | |
| RU2015101697A (ru) | Аналоги глюкагона, обладающие активностью рецептора gip | |
| US20160137712A1 (en) | Fusion Proteins With Dual Receptor Agonist Activities | |
| RU2011147083A (ru) | Новый вариант эксендина и его конъюгат | |
| RU2017101436A (ru) | Mic-1 слитные белки и их применение | |
| CN108271356A (zh) | 肠降血糖素-胰岛素缀合物 | |
| JP2016512213A5 (cg-RX-API-DMAC7.html) | ||
| KR20170068553A (ko) | 인터류킨-15 조성물 및 이의 용도 | |
| JP2008529558A5 (cg-RX-API-DMAC7.html) | ||
| RU2014101697A (ru) | Коагонисты рецепторов глюкагона/glp-1 | |
| JP2014525901A5 (cg-RX-API-DMAC7.html) | ||
| JP2015520128A5 (cg-RX-API-DMAC7.html) | ||
| AU2012286048A1 (en) | Long acting luteinizing hormone (LH) compound | |
| Romano et al. | Molecular cloning and characterization of CD4 in an aquatic mammal, the white whale Delphinapterus leucas | |
| JP2010535488A (ja) | インターフェロン融合タンパク質 | |
| JP7847083B2 (ja) | インターロイキン2キメラ構築物 | |
| JP2012518669A5 (cg-RX-API-DMAC7.html) | ||
| EP2263684A1 (en) | IL-21 derivatives | |
| ES2240475T3 (es) | Peptidos terapeuticos. | |
| De Rose et al. | Ovine interleukin-12: analysis of biologic function and species comparison | |
| JP2023505190A5 (cg-RX-API-DMAC7.html) | ||
| Yoo et al. | Molecular characterization of duck interleukin-17 |